THERAVANCE BIOPHARMA INC (TBPH)
KYG8807B1068 - Common Stock
| 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | 2019 (2019-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| CASH FLOWS FROM OPERATING ACTIVITIES | ||||||||
| Net Income | -55.19M | -92.82M | -199.43M | -278.02M | -236.46M | |||
| Depreciation Amortization | 2.00M | 3.72M | 5.91M | 6.80M | 6.44M | |||
| Income Taxes - Deferred | 3.21M | N/A | N/A | N/A | N/A | |||
| Change In Working Capital | -8.34M | 42.35M | -39.58M | -39.46M | -45.40M | |||
| Interest Paid | 0.00 | 22.24M | 39.03M | 24.02M | 26.18M | |||
| Taxes Paid | 24.00K | 117.97M | 4.09M | 10.00K | 20.00K | |||
| Other non cash items | 31.33M | -140.23M | 25.24M | 60.28M | 37.22M | |||
| OPERATING CASH FLOW | -27.00M | -186.99M | -207.86M | -250.40M | -238.20M | |||
| CASH FLOWS FROM INVESTING ACTIVITIES | ||||||||
| Capital Expenditure | -2.49M | -570.00K | -3.41M | -6.62M | -3.18M | |||
| Other Investing Activity | -30.21M | 1.15B | 127.90M | 17.34M | -79.88M | |||
| INVESTING CASH FLOW | -32.70M | 1.15B | 124.49M | 10.72M | -83.05M | |||
| CASH FLOWS FROM FINANCING ACTIVITIES | ||||||||
| Debt Issued/Reduced | 0.00 | -631.60M | -10.73M | 127.86M | -2.15M | |||
| Stock Issued/Repurchased | -199.55M | -132.28M | 99.12M | 131.53M | -30.00K | |||
| Other Financing Activity | 618.00K | 5.08M | 3.47M | 3.70M | 3.47M | |||
| FINANCING CASH FLOW | -198.93M | -758.81M | 91.86M | 263.09M | 1.29M | |||
| CHANGE IN CASH | -258.63M | 208.21M | 8.49M | 23.41M | -319.96M | |||
| FREE CASH FLOW | ||||||||
| Operating Cash Flow | -27.00M | -186.99M | -207.86M | -250.40M | -238.20M | |||
| Capital Expenditure | -2.49M | -570.00K | -3.41M | -6.62M | -3.18M | |||
| FREE CASH FLOW | -29.48M | -187.56M | -211.27M | -257.02M | -241.38M | |||
All data in USD